Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its AD04 is designed to reduce alcohol consumption without the need for inpatient stays. The molecule being explored, ondansetron, is widely used, well-characterized, and has shown promising data to fill a gap where other treatments for alcohol use disorder fall short, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADIL:
- Adial Pharmaceuticals expects cash to fund operations into second half of 2025
- Adial Pharmaceuticals Approves Strategic Changes at Annual Meeting
- Adial Pharmaceuticals Appoints New Chief Financial Officer
- Adial Pharmaceuticals appoints Shah as Chief Financial Officer
- Adial receives notice of allowance for U.S. patent related to AD04